Spotlight on cancer

Join the hunt for biomarkers

Daniel Hayes has watched the identification of biological markers of disease go from a “sleepy niche” to an increasingly important aspect of personalized care. “When I started, there was little funding for tumour biomarkers in any way, shape or form in the clinic, and there was little if any academic credit given for doing so,” says the cancer researcher at the University of Michigan in Ann Arbor.

Paul Smaglik

Please click here for a PDF of the full Spotlight.